1. Use of 13‐valent pneumococcal conjugate vaccine and 23‐valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP);Tomczyk S;MMWR Morb Mortal Wkly Rep,2014
2. MatanockA.Considerations for PCV13 use among adults >65 years old and a summary of the evidence to recommendations framework. Advisory Committee on Immunization Practices June 2019 Meeting.https://stacks.cdc.gov/view/cdc/80462. Accessed November 7 2019.
3. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
4. LeidnerAL. Overview of three economic analyses of pneumococcal vaccinations at age 65. Advisory Committee on Immunization Practices February 2019 Meetinghttps://stacks.cdc.gov/view/cdc/78093. Accessed November 7 2019.
5. PilishviliT.Impact of PCV13 on invasive pneumococcal disease (IPD) burden and the serotype distribution in the U.S. Advisory Committee on Immunization Practices October 24 2018.https://stacks.cdc.gov/view/cdc/61449. Accessed November 7 2019.